tbuckley/cabot-search huggingface dataset:
Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
Authors: Jorge E. Cortes, Clara Chen, Catherine Davis, Stuart L. Goldberg, Michael J. Mauro
Journal: Blood (2019)
CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma
Authors: Peter Herhaus, Jana Lipkova, Felicitas Lammer, Julia Slotta-Huspenina, Benedikt Wiestler, Tibor Vag, Stefan Habringer, Igor Yakushev, Constantin Lapa, Tobias Pukrop, Dirk Hellwig, Andreas Buck, Martina Deckert, Hans-Jürgen Wester, Florian Bassermann, Wolfgang Weber, Markus Schwaiger, Björn Menze, Ulrich Keller
Journal: Blood (2019)
Selective phytochemicals targeting pancreatic stellate cells as new anti-fibrotic agents for chronic pancreatitis and pancreatic cancer
Authors: Puvanesswaray Ramakrishnan, Wei Mee Loh, Subash C.B. Gopinath, Srinivasa Reddy Bonam, Ismail M. Fareez, Rhanye Mac Guad, Maw Shin Sim, Yuan Seng Wu
Journal: Acta Pharmaceutica Sinica B (2019)

Activated pancreatic stellate cells (PSCs) have been widely accepted as a key precursor of excessive pancreatic fibrosis, which is a crucial hallmark of chronic pancreatitis (CP) and its formidable associated disease, pancreatic cancer (PC). Hence, anti-fibrotic therapy has been identified as a novel therapeutic strategy for treating CP and PC by targeting PSCs. Most of the anti-fibrotic agents have been limited to phase I/II clinical trials involving vitamin analogs, which are abundant in medicinal plants and have proved to be promising for clinical application. The use of phytomedicines, as new anti-fibrotic agents, has been applied to a variety of complementary and alternative approaches. The aim of this review was to present a focused update on the selective new potential anti-fibrotic agents, including curcumin, resveratrol, rhein, emodin, green tea catechin derivatives, metformin, eruberin A, and ellagic acid, in combating PSC in CP and PC models. It aimed to describe the mechanism(s) of the phytochemicals used, either alone or in combination, and the associated molecular targets. Most of them were tested in PC models with similar mechanism of actions, and curcumin was tested intensively. Future research may explore the issues of bioavailability, drug design, and nano-formulation, in order to achieve successful clinical outcomes with promising activity and tolerability.
Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Authors: Dana L. Casey, Leonard H. Wexler, Kenneth L. Pitter, Robert M. Samstein, Emily K. Slotkin, Suzanne L. Wolden
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Increased availability of next-generation sequencing has allowed for the genomic characterization of a variety of pediatric tumors, although genomic determinants of response to treatment remain largely unknown. We sought to evaluate the genomic landscape and genomic determinants of clinical outcomes in rhabdomyosarcoma (RMS). Experimental Design: Of 29,067 patients who underwent genomic profiling at our institution using a 468-gene oncopanel with complete records, 87 had RMS, of whom 22 were fusion positive. The 10 most common genetic alterations were associated with locoregional control (LC), disease-free survival (DFS), and overall survival (OS). Tumor mutational burden (TMB), defined as the total number of somatic nonsynonymous mutations normalized to the number of sequenced megabases, was also associated with clinical outcomes. Results: Median age at diagnosis was 16.4 years and median follow-up, 2.1 years. Patients with fusion-negative RMS had more genomic alterations and a higher TMB than those with fusion-positive RMS (mean number of genomic alterations, 6.0 vs. 2.9; P = 0.007 and mean TMB, 2.6 vs. 1.0; P = 0.01). Genetic alterations in TP53 were associated with worse OS (P = 0.03). High TMB (defined as the top quartile ≥ 2.8) was associated with worse LC (P = 0.05), DFS (P = 0.04), and OS (P = 0.01), with significance retained on multivariable analysis after controlling for risk group, fusion status, and receipt of chemotherapy as per pediatric protocols. Conclusions: High TMB was associated with worse clinical outcomes in patients with RMS. With further validation, TMB and other genomic classifiers may be combined with traditional clinicopathologic risk factors to guide risk stratification and ultimately treatment decisions.
EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab
Authors: Frits van Rhee, Sharmilan Thanendrarajan, Carolina D. Schinke, Jeffery R. Sawyer, Adam Rosenthal, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, Mariam M. Boota, Clyde Bailey, Brian A Walker, Antje Hoering, Gareth Morgan, Maurizio Zangari, Faith E. Davies
Journal: Blood (2019)
Treatment of Tetanus
Authors: Meyer A. Perlstein
Journal: JAMA (1969)

<h3>To the Editor:—</h3> In the article on tetanus by Wessler, Avioli (<b>207</b>:123, 1969), no mention is made of the use of intramuscularly administered meprobamate in this patient, which in our experience has been the best method of controlling the spasms of tetanus. Since using this drug in our Tetanus Service at the Cook County Hospital in Chicago, we have no longer used darkened or sound-proof rooms, since there is no need for them. It appears that meprobamate (which is available as 400 mg in a 5-cc ampule of propylene glycol) given in this manner stops all spasms due to somatically induced stimuli. Thus, after giving this to a patient with tetanus, he can be stuck with a needle without having a spasm. Neither will shiny lights or noise cause a spasm. The drug, however, is not effective in stopping viscerally induced spasms. Thus, such a patient, even if given
Erythroferrone Regulates Bone Remodeling in β-Thalassemia
Authors: Melanie Castro-Mollo, Marc Ruiz Martinez, Maria Feola, Anisa Azatovna Gumerova, Carla Casu, Robert E Fleming, Stefano Rivella, Tony Yuen, Mone Zaidi, Yelena Ginzburg
Journal: Blood (2019)
TET1 Modulates DNA Replication in Leukemia Cells Via a Catalytic-Independent Mechanism through Cooperating with KAT8
Authors: Hengyou Weng, Huilin Huang, He Huang, Zhaojin Yu, Paulina Siejka-Zielinska, Zhenhua Chen, Emily Prince, Chao Shen, Zejuan Li, Chunxiao Song, Yingming Zhao, Jianjun Chen
Journal: Blood (2019)
Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)
Authors: Deeksha Vishwamitra, Christine Mantis, Dipica Haribhai, Tamar Uziel, Joel D. Leverson, James M. Pauff, Orlando F. Bueno, Paulo C. Maciag, Jeremy A. Ross
Journal: Blood (2019)
Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia
Authors: Colin D. Godwin, Olivia M. Bates, Sae Rin Jean, George S. Laszlo, Eliotte E. Garling, Mary E. Beddoe, Michael H. Cardone, Roland B. Walter
Journal: Blood (2019)
Global information flow
Authors: F. Godlee
Journal: BMJ (2000)

Information in practice p 797 

Might information flow be one of the most important factors for improving health and development in resource poor settings? Development organisations have not thought so. They have concentrated on infrastructural projects, increasing the number of health workers and clinics, and programmes to eradicate infections. But now we are at the start of the information age, and we understand better the importance of information. The recent millennium assembly of the United Nations emphasised this in its statement on the right of access to information and communication. Information underpins the learning, research, and debate that drives a country forward. Access to information is essential for describing and understanding the deficiencies of the present, building visions of a better future, developing practical ways to achieve those visions, and educating and inspiring those who must make the future. Information empowers, and those who work with information must realise that its flow, like good communication, must be two way.

The information gap between the rich and the poor is currently widening, both between and within countries.1 2 The digital divide is more dramatic than any other inequity in health or income.1 This lack of information persists—those medical libraries in sub-Saharan Africa that have had no current journals for years still don't have them.1–5 Meanwhile, the electronic revolution is providing scientists and health workers in the developed …
Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
Authors: Nirav N. Shah, Fenlu Zhu, Dina Schneider, Winfried Krueger, Andrew Worden, Walter L. Longo, Mehdi Hamadani, Timothy S. Fenske, Boro Dropulic, Rimas J Orentas, Parameswaran Hari, Bryon Johnson
Journal: Blood (2019)
m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation
Authors: Ruobing Jia, Peiwei Chai, Shanzheng Wang, Baofa Sun, Yangfan Xu, Ying Yang, Shengfang Ge, Renbing Jia, Yun-Gui Yang, Xianqun Fan
Journal: Molecular Cancer (2019)

Abstract Background Dynamic N 6 -methyladenosine (m 6 A) RNA modification generated and erased by N 6 -methyltransferases and demethylases regulates gene expression, alternative splicing and cell fate. Ocular melanoma, comprising uveal melanoma (UM) and conjunctival melanoma (CM), is the most common primary eye tumor in adults and the 2nd most common melanoma. However, the functional role of m 6 A modification in ocular melanoma remains unclear. Methods m 6 A assays and survival analysis were used to explore decreased global m 6 A levels, indicating a late stage of ocular melanoma and a poor prognosis. Multiomic analysis of miCLIP-seq, RNA-seq and Label-free MS data revealed that m 6 A RNA modification posttranscriptionally promoted HINT2 expression. RNA immunoprecipitation (RIP)-qPCR and dual luciferase assays revealed that HINT2 mRNA specifically interacted with YTHDF1. Furthermore, polysome profiling analysis indicated a greater amount of HINT2 mRNA in the translation pool in ocular melanoma cells with higher m 6 A methylation. Results Here, we show that RNA methylation significantly inhibits the progression of UM and CM. Ocular melanoma samples showed decreased m 6 A levels, indicating a poor prognosis. Changes in global m 6 A modification were highly associated with tumor progression in vitro and in vivo. Mechanistically, YTHDF1 promoted the translation of methylated HINT2 mRNA, a tumor suppressor in ocular melanoma. Conclusions Our work uncovers a critical function for m 6 A methylation in ocular melanoma and provides additional insight into the understanding of m 6 A modification.
Winter pressure: high demand, pension crisis, and flu could be “perfect storm” for NHS, warns BMA
Authors: Gareth Iacobucci
Journal: BMJ (2019)

Over a million patients could wait for over four hours at emergency departments this winter, and almost a third of a million could wait on trolleys, the BMA has warned.

In an analysis of current performance data and trends,1 the association has predicted that the NHS is on track to endure its worst ever winter as pressure on services intensifies in the coming months.

It said that a lack of recovery from the summer, staff shortages exacerbated by pension tax legislation forcing senior doctors to work fewer …
A Novel Method for Identifying Transgender and Gender Diverse Patients with Lymphoma: A Single Center Experience
Authors: Alison B Alpert, Shea A Nagle, Manuel J Greer, Philip J Meacham, Peter Macdowell, Nicholas Gerbino, Myla Strawderman, Kyle Trenshaw, Tina Faugh, Carla Casulo
Journal: Blood (2019)
Analysis and utility of pretreatment and posttreatment total body iodine-131 scans in patients with thyroid carcinoma
Authors: S. Billan, H. Nasrallah, R. Abdah-Bortnyak, A. Kuten
Journal: Journal of Clinical Oncology (2009)

e17031 Background: The purpose of this study was to evaluate the efficacy of post-I-131 treatment total body scans. Methods: The records of 108 consecutive patients with thyroid carcinoma treated by surgery and postoperative I-131 were reviewed. All patients underwent a postoperative diagnostic total body I-131 and post I-131 therapy scintigraphies .83% of patients were considered low risk according to AMES (age, metastasis, extracapsular extension, size) criteria. Results: The postoperative diagnostic total body I-131 scintigraphy revealed uptake in the neck in 95 out of 108 patients (88%). Three patients had lung and mediastinal uptake in known sites of metastatic disease. Additional foci of neck, mediastinal and lung uptake were revealed in the post-131 therapy total body scintigraphies in ten patients ( 9.3%). Variables found to correlate significantly with additional uptake on the post-I131 therapy total body scintigraphies were tumor size &gt;4cm, lymph-node involvement and extracapsular extension. Conclusions: Post- I-131 therapy scans yielded additional information in 9.3% of the patients treated by postoperative I-131 for well differentiated thyroid carcinoma. The value of posttreatment scintigraphies is questionable in low risk patients. No significant financial relationships to disclose.
Elective Splenectomy in Immune Thrombocytopenic Purpura: An Analysis of National Inpatient Sample (NIS) Database between Years 2006 and 2014
Authors: Sunny R K Singh, Sindhu Malapati, Rohit Kumar, Prasanth Lingamaneni, Leila Khaddour, Vijayalakshmi Donthireddy
Journal: Blood (2019)
Optimizing the Use of Heart Transplant in the United States
Authors: Alexander T. Sandhu, Y. Joseph Woo, Kiran K. Khush
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SCIDOT-18. NANOTHERAPEUTICS FOR NEUROSURGICALLY-APPLIED DRUG DELIVERY
Authors: Catherine Vasey, Vincenzo Taresco, Stuart Smith, Cameron Alexander, Ruman Rahman
Journal: Neuro-Oncology (2019)

Abstract Design and implementation of innovative local drug delivery systems (DDS) may overcome current limitations in GBM treatment, such as the lack of therapeutic drug concentrations reaching residual GBM cells following surgery. Here we describe a novel DDS which utilises a bespoke mechanically engineered spray device, designed for safe surgical use, to deliver a mucoadhesive hydrogel containing chemotherapeutic nanoparticles (NPs) into the tumour resection margins. The overall aim is to spray a NP and polymer solution onto the resection cavity and potentially increase penetration of anti-cancer drugs within the 2 cm reoccurrence zone beyond the infiltrative margin. The mucoadhesive gel of choice, pectin, is currently used in other in vivo applications; however we have repurposed this for the brain. Pectin is biocompatible with GBM and human astrocyte cells in vitro and showed neither toxicity nor inflammation for up to 2 weeks upon orthotopic brain injection. Pectin is biodegradable in artificial CSF and is capable of being sprayed from the engineered device. A panel of polymeric, oil-based and polymer-coated NPs have been developed and optimised to maximise drug encapsulation of etoposide and olaparib as proof-of-concept for combination drug delivery. Etoposide/olaparib was chosen due to cytotoxicity from 5 GBM cell lines, including primary lines isolated from the invasive tumour margin (Mean IC50 of 1.1 µM and 8.3 µM respectively). The optimal NP/drug formulation (based on drug encapsulation, spray capability and bio-adhesiveness) will ultimately be assessed for tolerability and efficacy using orthotopic allograft and xenograft high-grade glioma models, including measurement of penetration of drug/nanoparticle in ex vivo murine and porcine brain using novel hybrid time-of-flight/Orbitrap TM secondary ion mass spectrometer (orbiSIMS) technology.
Rheumatoid Arthritis as a New Disease-Target for Bortezomib.
Authors: Evangelia Yannaki, Anastasia Papadopoulou, Argyrw Paraskeva, Panayotis Kaloyannidis, Evangelia Athanasiou, Dimitris Bougiouklis, Panayotis Palladas, Minas Yiangou, Athanasios Fassas, Achilles Anagnostopoulos
Journal: Blood (2008)
Early intervention with atorvastatin modulates Th1/Th2 imbalance in patients with acute coronary syndrome : From bedside to bench - Response
Authors: S Kinlay, P Libby, P Ganz, GG Schwartz, Anders Olsson, SJ Leslie, WJ Sasiela, M Szarek
Journal: Circulation (2004)

Early intervention with atorvastatin modulates Th1/Th2 imbalance in patients with acute coronary syndrome :  From bedside to bench - Response
Evaluation of mouse polyclonal antibody against nNav1.5 to recognize nNav1.5 protein in human breast cancer cells using fluorescence immunostaining
Authors: N.F. Mokhtar, N.A. Sharuddin, N.F.A. Che Wahab, A.A. Dominguez, M.E. Sarmiento, N. Mohd Nor, N.S. Yaccob
Journal: Annals of Oncology (2019)
CMET-27. EVALUATION OF DYNAMIN 2 (DNM2) AS A THERAPEUTIC TARGET IN LEPTOMENINGEAL METASTATIC DISEASE
Authors: Sophia Chernikova, Dina Polyak, Jiaojiao Deng, Sheila Tsau, Kerriann Casey, Eli Johnson, Hriday Bhambhvani, Lina Khoeur, Geoff Stanley, Kevin Tran, Ian Connolly, Annie Joyce, Yingmei Li, Rie von Eyben, Seema Nagpal, Melanie Hayden Gephart
Journal: Neuro-Oncology (2019)

Abstract Leptomeningeal metastasis (LM), a spread of cancer to the meninges and cerebrospinal fluid, carries extremely poor prognosis due to fast progression and no effective treatment. Given that LM mostly develops in specific types of cancer, notably melanoma, breast and lung cancer, it is likely that predisposition for LMD is shaped by specific genetic footprints and/or anti-cancer therapies. In this regard, it is interesting that among all breast cancers the triple-negative (i.e. estrogen and progesterone receptor-negative and HER2 overexpression-negative) breast cancer (TNBC) type develops a disproportionally high percentage of LM, accounting for the majority (~40%) of all breast cancer LM cases. TNBCs trace their origin to the genomic instability stemming from defects in DNA repair (notably homology-directed repair, HDR). We have recently shown that the efficiency of HDR depends on dynamin 2 (DNM2) best known for its role in endocytic protein trafficking. Higher DNM2 was associated with more efficient HDR and the resistance to DNA-crosslinking chemotherapy. Importantly, elevated DNM2 was associated with lower relapse-free survival and shorter times to relapse after chemotherapy only in TNBCs and not in other types of breast cancer. As DNM2 also fuels migration and invasion, the cells with high DNM2 are not only the most resistant to chemotherapy but also are the most mobile, and thus may represent the core population of LM. Here we test the inhibition of the DNM2-dependent endocytic trafficking as a potential therapeutic strategy to halt LM in TNBC. As a model of LM we use the human-in-mouse model of brain metastasis based on internal carotid injection of MDA-MB-231-BR3 cells, which we have shown to faithfully recapitulate human LM. We show that DNM2 knockdown delays metastatic spread to the brain and potentiates the effect of DNA-crosslinking chemotherapeutic cyclophosphamide, providing justification for further testing of DNM2 inhibitors for targeted therapy of LM.
Generation of functional lungs via conditional blastocyst complementation using pluripotent stem cells
Authors: Munemasa Mori, Kazuhiro Furuhashi, Jennifer A. Danielsson, Yuichi Hirata, Miwako Kakiuchi, Chyuan-Sheng Lin, Mayu Ohta, Paul Riccio, Yusuke Takahashi, Xinjing Xu, Charles W. Emala, Chao Lu, Hiromitsu Nakauchi, Wellington V. Cardoso
Journal: Nature Medicine (2019)
The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blown Disease Based on Age of Onset
Authors: Louis Williams, Eileen M Boyle, Faith E. Davies, Brian A Walker, Cody Ashby, Michael A Bauer, Christopher P. Wardell, Erin Flynt, Anjan Thakurta, Gareth Morgan
Journal: Blood (2019)
PDTC-17. A RETROSPECTIVE STUDY OF RECOMBINANT HUMAN ENDOSTATIN COMBINED WITH CARBOPLATIN AND VINCRISTINE FOR PEDIATRIC LOW-GRADE GLIOMAS
Authors: Jun-Ping Zhang
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE To analyze the response and toxicity of recombinant human endostatin (rh-ES) combined with carboplatin and vincristine (CV) chemotherapy regimen for pediatric low-grade gliomas (LGGs). METHODS Retrospectively reviewed the clinical data of the patients who were received rh-ES with CV chemotherapy regimen at Department of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University from October 2014 to October 2018. Carboplatin was administrated at a dose of 200~300 mg/m2 and the vincristine dose was 1.5 mg/m2 (maximum dose: 2 mg). Rh-ES was administrated 15 mg/d, daily for 14 days of each 28-day treatment cycle. RESULTS 26 patients were enrolled. By the time of the last follow-up, 14 patients had completed the treatment and 6 were still in treatment. Of the 26 patients, 14 had partial response (PR), 12 had stable disease (SD), and the objective response rate (ORR) was 53.8%. Of the 14 patients who completed all the treatment, 10 achieved PR, 4 got SD, and the ORR was 71.4%. The median time interval to response was 3.3 months (range 2–12.6 months). The main adverse reactions were myelosuppression and allergy to carboplatin. Three patients were terminated in the consolidation phase due to adverse reactions. CONCLUSIONS The rh-ES combined with CV regimen is effective in the treatment of pediatric LGGs and had a rapid time interval to response, which is conducive to the rapid relief of brain stem or visual function damage.
Barrett Özofagusunda Mukoza İçi Karsinomu ve İleri Derece Displaziyi Tanımlamak İçin Optik Tutarlık Tomografisi
Authors: John A. Evans, John M. Poneros, Brett E. Bouma, Jason Bressner, Elkan F. Halpern, Milen Shishkov, Gregory Y. Lauwers, sup> Mari Mino-Kenudson #<, sup> Norman S. Nishioka, sup> ve Guillermo J. Tearney #
Journal: Clinical Gastroenterology and Hepatology (2006)
Causes of Death in 198 Sickle Cell Adult Patients: Old and New Trends
Authors: Anoosha Habibi, Stephanie Ngo, Etienne Audureau, Armand Mekontso-Dessap, Keyvan Razazi, Elena Foïs, Thibaud Damy, France Pirenne, Marc Michel, Vincent Audard, Frédéric Galactéros, Pablo Bartolucci
Journal: Blood (2019)
使用最佳防晒霜可促进维生素 D 合成
Authors: A.R. Young, J. Narbutt, G.I. Harrison, K.P. Lawrence, M. Bell, C. O'Connor, P. Olson, K. Grys, K.A. Baczynska, M. Rogowski‐Tylman, H.C. Wulf, A. Lesiak, P.A. Philipsen
Journal: British Journal of Dermatology (2019)

维生素 D 对骨骼健康至关重要,它是皮肤受阳光中紫外线(UVR)的照射后产生的。但是,UVR 不仅是维生素 D 的主要来源,也是皮肤癌的主要原因。这引发了有关如何预防维生素 D 含量过低,同时又限制皮肤癌风险的疑问。 这项由伦敦国王学院的研究人员主导的研究发现,防晒霜并不会影响大多数人在紫外线指数很高地区的为期一周度假中摄入足够的维生素 D。 在度假期间,有 20 人使用广谱防晒霜,其防晒系数(SPF)为 15,可提供 UVB 防护和高 UVA 防护效果。另 20 人使用非广谱防晒霜,SPF 15,但 UVA 防护效果较低。告诉这两组人如何正确使用防晒霜以达到标签所示的 SPF。 相反,22 人使用了自己的防晒霜,无使用说明,17 人组成对照组,他们留在波兰。在度假前 24 小时和度假后 24 至 48 小时,从参与者中采集血液样本,以检查维生素 D 水平。 前两组的维生素 D 水平显著改善。使用自己的防晒霜的组中,也有大量维生素 D 合成,但所有人都出现晒伤。同一时期,对照组的维生素 D 略有下降。